Recent Research Analysts’ Ratings Changes for Rapport Therapeutics (RAPP)

A number of research firms have changed their ratings and price targets for Rapport Therapeutics (NASDAQ: RAPP):

• 10/6/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 10/5/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 10/5/2026 – Rapport Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $65.00 price target on the stock.
• 9/23/2026 – Rapport Therapeutics was given a new $80.00 price target by UBS Group AG.
• 9/23/2026 – Rapport Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/22/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc..
• 9/16/2026 – Rapport Therapeutics had its price target raised by BTIG Research from $65.00 to $75.00. They now have a “buy” rating on the stock.
• 8/19/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $65.00 price target on the stock.
• 8/17/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $75.00 price target on the stock.
• 8/17/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by UBS Group AG.
• 8/12/2026 – Rapport Therapeutics had its price target raised by HC Wainwright from $40.00 to $66.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, COO Cheryl Gault sold 10,000 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $33.19, for a total transaction of $331,900.00. Following the transaction, the chief operating officer owned 139,914 shares of the company’s stock, valued at $4,643,745.66. The trade was a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Abraham Ceesay sold 28,958 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the transaction, the chief executive officer directly owned 486,108 shares in the company, valued at $23,338,045.08. The trade was a 5.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 93,454 shares of company stock valued at $4,277,081 in the last 90 days. 12.48% of the stock is currently owned by insiders.

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system.

Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy.